Dr Peter Toth discusses with Dr. Thomas Nero the new classes of diabetes medications, SGLT2 inhibitors (eg Jardiance) and GLP1 receptor agonists (eg Ozempic and Munjaro.) These drugs have been in the news due to an impressive effect on weight reduction, but they also improve cardiovascular outcomes in diabetic and non-diabetic patients.